chloroquine has been researched along with Graft vs Host Disease in 10 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Graft vs Host Disease: The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have recently shown that the lysosomotropic amine, chloroquine, can inhibit the development of graft-versus-host disease (GVHD) secondary to minor histocompatibility (MiHC) differences in mice." | 8.79 | The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease. ( Gilman, AL; Schultz, KR, 1997) |
| "Chloroquine treatment decreased the proliferative T-cell response to MiHC by 67% and the cytolytic T-cell activation by greater than 50%." | 5.29 | Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease. ( Bader, S; Li, W; Paquet, J; Schultz, KR, 1995) |
| "We have recently shown that the lysosomotropic amine, chloroquine, can inhibit the development of graft-versus-host disease (GVHD) secondary to minor histocompatibility (MiHC) differences in mice." | 4.79 | The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease. ( Gilman, AL; Schultz, KR, 1997) |
| "The 4-aminoquinolines, chloroquine and hydroxychloroquine, can suppress chronic graft-versus-host disease (GVHD) following blood and marrow transplantation (BMT) in mice and humans, respectively." | 3.71 | Evaluation for synergistic suppression of T cell responses to minor histocompatibility antigens by chloroquine in combination with tacrolimus and a rapamycin derivative, SDZ-RAD. ( Bader, S; Forooghian, F; Gilman, A; HayGlass, KT; Hsiao, CC; Rempel, J; Schultz, KR; Su, WN, 2002) |
| "Previously, it has been shown that the lysosomotropic amine, chloroquine, is effective in the prevention of graft-versus-host disease (GVHD) using murine models." | 3.69 | Synergy between lysosomotropic amines and cyclosporin A on human T cell responses to an exogenous protein antigen, tetanus toxoid. ( Bader, S; Nelson, D; Schultz, KR, 1996) |
| "Using murine models, we have shown that the lysosomotropic amine, chloroquine, is effective in the prevention of graft-versus-host disease (GVHD) mediated by donor T cells reactive with recipient minor histocompatibility antigens (MiHCs)." | 3.69 | Immune suppression by lysosomotropic amines and cyclosporine on T-cell responses to minor and major histocompatibility antigens: does synergy exist? ( Bader, S; HayGlass, KT; Nelson, D; Schultz, KR; Wang, MD, 1997) |
| "Chloroquine treatment decreased the proliferative T-cell response to MiHC by 67% and the cytolytic T-cell activation by greater than 50%." | 1.29 | Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease. ( Bader, S; Li, W; Paquet, J; Schultz, KR, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (70.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hsiao, CC | 2 |
| Su, WN | 2 |
| Forooghian, F | 1 |
| Bader, S | 5 |
| Rempel, J | 1 |
| HayGlass, KT | 2 |
| Gilman, A | 1 |
| Schultz, KR | 6 |
| Doho, G | 1 |
| Jevon, G | 1 |
| MacFarlane, DE | 1 |
| Gilman, AL | 2 |
| Paquet, J | 1 |
| Li, W | 1 |
| Nelson, D | 2 |
| Nishimura, M | 2 |
| Akaza, T | 2 |
| Tadokoro, K | 2 |
| Juji, T | 2 |
| Wang, MD | 1 |
| Hidaka, N | 1 |
| Saigo, K | 1 |
| Ryo, R | 1 |
| Chen, W | 1 |
| Thoburn, CJ | 1 |
| Miura, Y | 1 |
| Sommer, M | 1 |
| Hruban, R | 1 |
| Qian, Z | 1 |
| Baldwin, W | 1 |
| Hess, AD | 1 |
2 reviews available for chloroquine and Graft vs Host Disease
| Article | Year |
|---|---|
The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease.
Topics: Animals; Antigen Presentation; Bone Marrow Transplantation; Chloroquine; Clinical Trials as Topic; C | 1997 |
Therapeutic strategy for post-transfusion graft-vs.-host disease.
Topics: Antirheumatic Agents; Chloroquine; Enzyme Inhibitors; Graft vs Host Disease; Humans; Immunosuppressi | 1999 |
8 other studies available for chloroquine and Graft vs Host Disease
| Article | Year |
|---|---|
Evaluation for synergistic suppression of T cell responses to minor histocompatibility antigens by chloroquine in combination with tacrolimus and a rapamycin derivative, SDZ-RAD.
Topics: Animals; Antigen Presentation; Apoptosis; Cells, Cultured; Chloroquine; Cytokines; Drug Evaluation, | 2002 |
Chloroquine prevention of murine MHC-disparate acute graft-versus-host disease correlates with inhibition of splenic response to CpG oligodeoxynucleotides and alterations in T-cell cytokine production.
Topics: Animals; Bone Marrow Transplantation; Chloroquine; Cytokines; Dinucleoside Phosphates; Female; Graft | 2002 |
Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease.
Topics: Animals; Antigen Presentation; B-Lymphocytes; Bone Marrow Transplantation; CD4-Positive T-Lymphocyte | 1995 |
Synergy between lysosomotropic amines and cyclosporin A on human T cell responses to an exogenous protein antigen, tetanus toxoid.
Topics: Adult; Antigens, Differentiation, B-Lymphocyte; Chloroquine; Cyclosporine; Drug Synergism; Graft vs | 1996 |
Potential usefulness of protease inhibitor and chloroquine in the treatment of transfusion-associated graft-versus-host disease.
Topics: Antigen-Presenting Cells; Antimalarials; Benzamidines; Chloroquine; Cytotoxins; Graft vs Host Diseas | 1997 |
Immune suppression by lysosomotropic amines and cyclosporine on T-cell responses to minor and major histocompatibility antigens: does synergy exist?
Topics: Animals; Cell Survival; Cells, Cultured; Chloroquine; Concanavalin A; Cyclosporine; Drug Synergism; | 1997 |
Immunosuppressive effects of chloroquine: potential effectiveness for treatment of post-transfusion graft-versus-host disease.
Topics: Chloroquine; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Humans; Immunosuppress | 1998 |
Autoimmune-mediated vasculopathy.
Topics: Adoptive Transfer; Animals; Antigens, Differentiation, B-Lymphocyte; Arteriosclerosis; Autoimmune Di | 2001 |